肝细胞癌的新型全身治疗

StephenW

Novel systemic therapy for hepatocellular carcinoma

    Yawen Dong, Tsung-Hao Liu, Thomas Yau & Chiun Hsu

Hepatology International volume 14, pages638–651(2020)Cite this article

    364 Accesses

    Metrics details

Abstract

Systemic therapy for hepatocellular carcinoma (HCC) used to be limited to patients with advanced diseases and multi-kinase inhibitors targeting tumor angiogenesis the major approach of developing new treatment options. In the past 3 years, new data from trials of both molecular targeted therapy and immune checkpoint inhibitors (ICI) provided many new options of first- and second-line treatment for advanced HCC. Most notably, combination of ICI targeting the program cell death-1 (PD-1) pathway with other novel agents or conventional anti-cancer therapy may further improve treatment efficacy in different clinical settings. In this paper updated data of clinical trials of systemic therapy in the first- and second-line settings for advanced HCC were reviewed and the following issues were discussed: (1) lessons of trial design learned from positive and negative trials; (2) the balance between efficacy and safety in clinical practice; and (3) impact on future multi-disciplinary management of HCC.

StephenW

肝细胞癌的新型全身治疗

    董亚文，刘宗浩，邱国＆＆许建勋

《国际肝病学》第14卷，第638–651页（2020年）

    364次访问

    指标详细信息

抽象

肝细胞癌（HCC）的全身治疗过去仅限于患有晚期疾病的患者和针对肿瘤血管生成的多种激酶抑制剂，这是开发新治疗方案的主要方法。在过去的三年中，来自分子靶向疗法和免疫检查点抑制剂（ICI）的试验的新数据为晚期HCC的一线和二线治疗提供了许多新选择。最值得注意的是，靶向程序性细胞死亡-1（PD-1）途径的ICI与其他新型药物或常规抗癌疗法的结合可以进一步改善不同临床环境中的治疗功效。本文回顾了在晚期HCC的一线和二线环境中进行全身治疗的临床试验的更新数据，并讨论了以下问题：（1）从阳性和阴性试验中汲取的试验设计经验； （2）临床实践中疗效与安全性之间的平衡； （3）对HCC未来多学科管理的影响。